CYTOKINETICS, INCORPORATED Income (Loss) from Continuing Operations, Per Basic Share
CYTOKINETICS, INCORPORATED (CYTK) reported Income (Loss) from Continuing Operations, Per Basic Share of $0.22 per share for the 3-month period ending 2013-12-31, per its 10-K filed 2015-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2015-03-06
- CYTOKINETICS, INCORPORATED income (loss) from continuing operations, per basic share for the quarter ending 2013-12-31 was $0.22.
- CYTOKINETICS, INCORPORATED income (loss) from continuing operations, per basic share for the quarter ending 2013-09-30 was -$0.43.
- CYTOKINETICS, INCORPORATED income (loss) from continuing operations, per basic share for the quarter ending 2013-06-30 was -$0.58.
- CYTOKINETICS, INCORPORATED income (loss) from continuing operations, per basic share for the quarter ending 2013-03-31 was -$0.53.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month |
|---|---|
| 2013-12-31 | $0.22 10-K · filed 2015-03-06 |
| 2013-09-30 | -$0.43 10-K · filed 2015-03-06 |
| 2013-06-30 | -$0.58 10-K · filed 2015-03-06 |
| 2013-03-31 | -$0.53 10-K · filed 2015-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |